166 related articles for article (PubMed ID: 27349449)
1. Pyrrolidino Analogues of Gefitinib with Improved EGFR Inhibition, Cancer Cell Cytotoxicity, and Pharmacokinetic Properties.
Fang JK; Xu Z; Zhang Y; Zhang W; Liu B; Fang Y; Sun T
Anticancer Agents Med Chem; 2016; 16(12):1665-1672. PubMed ID: 27349449
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of Novel Thieno[2,3-d]pyrimidine Derivatives and Evaluation of Their Cytotoxicity and EGFR Inhibitory Activity.
Adly ME; Gedawy EM; El-Malah AA; El-Telbany FA
Anticancer Agents Med Chem; 2018; 18(5):747-756. PubMed ID: 29366427
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of novel pyridopyrimidine derivatives with anchoring non-coplanar aromatic extensions of EGFR inhibitory activity.
Eissa AAM; Aljamal KFM; Ibrahim HS; Abdelrasheed Allam H
Bioorg Chem; 2021 Nov; 116():105318. PubMed ID: 34488123
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and antitumor evaluation of novel 4-anilino-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate derivatives as potential EGFR inhibitors.
Zhang D; Yan Y; Jin G; Liu B; Ma X; Han D; Jia X
Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800110. PubMed ID: 30048007
[TBL] [Abstract][Full Text] [Related]
6. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
El-Sayed NA; Nour MS; Salem MA; Arafa RK
Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
[TBL] [Abstract][Full Text] [Related]
7. 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity.
Liu F; Tang B; Liu H; Li L; Liu G; Cheng Y; Xu Y; Chen W; Huang Y
Anticancer Agents Med Chem; 2016; 16(12):1652-1664. PubMed ID: 27039919
[TBL] [Abstract][Full Text] [Related]
8. New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancers.
Liu Z; Wang L; Feng M; Yi Y; Zhang W; Liu W; Li L; Liu Z; Li Y; Ma X
Bioorg Chem; 2018 Apr; 77():593-599. PubMed ID: 29482151
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis and Structure-Activity Relationships of Novel Diaryl Urea Derivatives as Potential EGFR Inhibitors.
Jiang N; Bu Y; Wang Y; Nie M; Zhang D; Zhai X
Molecules; 2016 Nov; 21(11):. PubMed ID: 27869742
[TBL] [Abstract][Full Text] [Related]
10. Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents.
Allam HA; Aly EE; Farouk AKBAW; El Kerdawy AM; Rashwan E; Abbass SES
Bioorg Chem; 2020 May; 98():103726. PubMed ID: 32171987
[TBL] [Abstract][Full Text] [Related]
11. 1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC.
Dokla EME; Fang CS; Abouzid KAM; Chen CS
Eur J Med Chem; 2019 Nov; 182():111607. PubMed ID: 31446247
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and anti-proliferative activity of some new quinoline based 4,5-dihydropyrazoles and their thiazole hybrids as EGFR inhibitors.
George RF; Samir EM; Abdelhamed MN; Abdel-Aziz HA; Abbas SE
Bioorg Chem; 2019 Mar; 83():186-197. PubMed ID: 30380447
[TBL] [Abstract][Full Text] [Related]
13. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents.
Yassen AS; Elshihawy HE; Said MM; Abouzid KA
Chem Pharm Bull (Tokyo); 2014; 62(5):454-66. PubMed ID: 24789927
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and assessment of new series of quinazolinone derivatives as EGFR inhibitors along with their cytotoxic evaluation against MCF7 and A549 cancer cell lines.
Aziz MW; Kamal AM; Mohamed KO; Elgendy AA
Bioorg Med Chem Lett; 2021 Jun; 41():127987. PubMed ID: 33771586
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of novel gefitinib-based derivatives and their anticancer activity.
Sharma MJ; Kumar MS; Murahari M; Mayur YC
Arch Pharm (Weinheim); 2019 May; 352(5):e1800381. PubMed ID: 31012144
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Anti-Proliferation Activity Evaluation of Novel 2-Chloroquinazoline as Potential EGFR-TK Inhibitors.
Zheng Q; Xu XB; Jin H; Zhang W; Rao GW
Chem Biodivers; 2021 Nov; 18(11):e2100478. PubMed ID: 34510749
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance.
Fischer T; Najjar A; Totzke F; Schächtele C; Sippl W; Ritter C; Hilgeroth A
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1-8. PubMed ID: 29098884
[TBL] [Abstract][Full Text] [Related]
18. Compounds Consisting of Quinazoline, Ibuprofen, and Amino Acids with Cytotoxic and Anti-Inflammatory Effects.
Garduño-Villavicencio LR; Martínez-Ortega U; Ortiz-Sánchez E; Tinajero-Rodríguez JM; Hernández-Luis F
ChemMedChem; 2024 May; 19(10):e202300651. PubMed ID: 38354370
[TBL] [Abstract][Full Text] [Related]
19. Novel 4-arylaminoquinazolines bearing
Zhang Y; Chen L; Li X; Gao L; Hao Y; Li B; Yan Y
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1668-1677. PubMed ID: 31530043
[TBL] [Abstract][Full Text] [Related]
20. Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
Chen L; Zhang Y; Liu J; Wang W; Li X; Zhao L; Wang W; Li B
Eur J Med Chem; 2017 Sep; 138():689-697. PubMed ID: 28711703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
